{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T18:46:20Z","timestamp":1787769980138,"version":"build-2784847793"},"reference-count":24,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2024,10,2]],"date-time":"2024-10-02T00:00:00Z","timestamp":1727827200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Med."],"abstract":"<jats:sec><jats:title>Introduction<\/jats:title><jats:p>Proliferative glomerulonephritis with monoclonal immunoglobulin deposits (PGNMID) is a chronic glomerular disease caused by monoclonal gammopathy. IgG (mainly IgG3) is the most commonly involved isotype of PGNMID. Here we illustrated a novel medication regimen for the rare variant of PGNMID with deposition of monoclonal immunoglobulin light chain only (PGNMID-LC). Daratumumab has been proved effective in the treatment of plasma cell myeloma while its effect for PGNMID-LC has rarely been reported.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>A daratumumab combination therapy (D-VCd regimen, specifically are daratumumab + dexamethasone + bortezomib + cyclophosphamide) was adopted to treat a patient diagnosed with PGNMID-LC.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>The utility of D-VCd regimen showed a favorable effect in this patient. After the fixed course, his clinical symptom, laboratory parameters, neoplastic plasma cells clonity all restored to normal range, and no obvious disease progression was observed throughout the treatment. After a follow up of 14\u2009months, no significant renal or hematological disease progression has been observed.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>This case underscores the utility of D-VCd regimen in treatment of PGNMID-LC, and it\u2019s inferred that daratumumab regimen has clinical effects in the disease primarily through targeting tumor clonity. However, data on the use of daratumumab (either in monotherapy or in combination) in clinical trials of PGNMID-LC is currently so limited that that more experiments are needed to support the inference.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fmed.2024.1462199","type":"journal-article","created":{"date-parts":[[2024,10,2]],"date-time":"2024-10-02T04:28:18Z","timestamp":1727843298000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":3,"title":["Case report: A case of proliferative glomerulonephritis with monoclonal kappa-light chain deposits treated with daratumumab combination therapy"],"prefix":"10.3389","volume":"11","author":[{"given":"Jue","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun-Ting","family":"Lv","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dan","family":"Xiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jia","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Du","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lu","family":"Zhong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2024,10,2]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1093\/ndt\/gfz176","article-title":"Proliferative glomerulonephritis with monoclonal immunoglobulin deposits: a nephrologist perspective","volume":"36","author":"Bridoux","year":"2021","journal-title":"Nephrol Dial Transplant"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1016\/j.kint.2019.10.025","article-title":"Light chain only variant of proliferative glomerulonephritis with monoclonal immunoglobulin deposits is associated with a high detection rate of the pathogenic plasma cell clone","volume":"97","author":"Nasr","year":"2020","journal-title":"Kidney Int"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"1041","DOI":"10.1093\/ckj\/sfab269","article-title":"An update of proliferative glomerulonephritis with monoclonal immunoglobulin deposits","volume":"15","author":"Li","year":"2022","journal-title":"Clin Kidney J"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"295","DOI":"10.4103\/ijpm.ijpm_505_21","article-title":"Immunophenotypic characterization of normal and abnormal plasma cells in bone marrow of newly diagnosed multiple myeloma patients","volume":"66","author":"Awasthi","year":"2023","journal-title":"Indian J Pathol Microbiol"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"2055","DOI":"10.1681\/ASN.2009010110","article-title":"Proliferative glomerulonephritis with monoclonal IgG deposits","volume":"20","author":"Nasr","year":"2009","journal-title":"J Am Soc Nephrol"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"4541","DOI":"10.1200\/JCO.2011.37.7614","article-title":"New criteria for response to treatment in immunoglobulin light chain amyloidosis based on free light chain measurement and cardiac biomarkers: impact on survival outcomes","volume":"30","author":"Palladini","year":"2012","journal-title":"J Clin Oncol"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1002\/ajh.20381","article-title":"Definition of organ involvement and treatment response in immunoglobulin light chain amyloidosis (AL): a consensus opinion from the 10th International Symposium on Amyloid and Amyloidosis, Tours, France, 18\u201322 April 2004","volume":"79","author":"Gertz","year":"2005","journal-title":"Am J Hematol"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1007\/s00467-024-06425-2","article-title":"Proliferative glomerulonephritis with monoclonal IgG deposits in an adolescent successfully treated with daratumumab","author":"Svabova","year":"2024","journal-title":"Pediatr Nephrol"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"1360979","DOI":"10.3389\/fmed.2024.1360979","article-title":"Promising response of proliferative glomerulonephritis with monoclonal IgG deposits to low-dose daratumumab: a case report","volume":"11","author":"Xu","year":"2024","journal-title":"Front Med"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1016\/j.kint.2018.02.020","article-title":"A clone-directed approach may improve diagnosis and treatment of proliferative glomerulonephritis with monoclonal immunoglobulin deposits","volume":"94","author":"Gumber","year":"2018","journal-title":"Kidney Int"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1038\/s41581-018-0077-4","article-title":"The evaluation of monoclonal gammopathy of renal significance: a consensus report of the International Kidney and Monoclonal Gammopathy Research Group","volume":"15","author":"Leung","year":"2019","journal-title":"Nat Rev Nephrol"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"2511","DOI":"10.1016\/j.ekir.2023.10.013","article-title":"The uncertainty puzzle of monoclonal gammopathy of renal significance without detectable clones","volume":"8","author":"Shah","year":"2023","journal-title":"Kidney Int Rep"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"2166","DOI":"10.1016\/j.ekir.2022.07.009","article-title":"Efficacy of immunomodulatory drugs in combination with dexamethasone in proliferative glomerulonephritis with monoclonal immunoglobulin deposits","volume":"7","author":"Zhou","year":"2022","journal-title":"Kidney Int Rep"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"1931","DOI":"10.1056\/NEJMra1810907","article-title":"Monoclonal gammopathy of renal significance","volume":"384","author":"Leung","year":"2021","journal-title":"N Engl J Med"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"1163","DOI":"10.1681\/ASN.2020101541","article-title":"Safety and efficacy of daratumumab in patients with proliferative GN with monoclonal immunoglobulin deposits","volume":"32","author":"Zand","year":"2021","journal-title":"J Am Soc Nephrol"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"1284","DOI":"10.1016\/j.mayocp.2013.08.002","article-title":"Monoclonal gammopathy-associated proliferative glomerulonephritis","volume":"88","author":"Sethi","year":"2013","journal-title":"Mayo Clin Proc"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1111\/bjh.15806","article-title":"Daratumumab, bortezomib, cyclophosphamide and dexamethasone in newly diagnosed and relapsed multiple myeloma: LYRA study","volume":"185","author":"Yimer","year":"2019","journal-title":"Br J Haematol"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1182\/blood.2019004460","article-title":"Daratumumab plus CyBorD for patients with newly diagnosed AL amyloidosis: safety run-in results of ANDROMEDA","volume":"136","author":"Palladini","year":"2020","journal-title":"Blood"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1053\/j.ajkd.2022.08.025","article-title":"Light chain-only immunotactoid glomerulopathy: a case report","volume":"81","author":"Bu","year":"2023","journal-title":"Am J Kidney Dis"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"520","DOI":"10.3390\/cells4030520","article-title":"NAD+-metabolizing ectoenzymes in remodeling tumor-host interactions: the human myeloma model","volume":"4","author":"Horenstein","year":"2015","journal-title":"Cells"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1080\/19420862.2015.1007813","article-title":"Antibody-mediated phagocytosis contributes to the anti-tumor activity of the therapeutic antibody daratumumab in lymphoma and multiple myeloma","volume":"7","author":"Overdijk","year":"2015","journal-title":"MAbs"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"1840","DOI":"10.4049\/jimmunol.1003032","article-title":"Daratumumab, a novel therapeutic human CD38 monoclonal antibody, induces killing of multiple myeloma and other hematological tumors","volume":"186","author":"de Weers","year":"2011","journal-title":"J Immunol"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"384","DOI":"10.1182\/blood-2015-12-687749","article-title":"Daratumumab depletes CD38+ immune regulatory cells, promotes T-cell expansion, and skews T-cell repertoire in multiple myeloma","volume":"128","author":"Krejcik","year":"2016","journal-title":"Blood"},{"key":"ref24","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1182\/blood-2017-06-740944","article-title":"CD38 antibodies in multiple myeloma: back to the future","volume":"131","author":"van de Donk","year":"2018","journal-title":"Blood"}],"container-title":["Frontiers in Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2024.1462199\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,2]],"date-time":"2024-10-02T04:28:20Z","timestamp":1727843300000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2024.1462199\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,2]]},"references-count":24,"alternative-id":["10.3389\/fmed.2024.1462199"],"URL":"https:\/\/doi.org\/10.3389\/fmed.2024.1462199","relation":{},"ISSN":["2296-858X"],"issn-type":[{"value":"2296-858X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,10,2]]},"article-number":"1462199"}}